prednisone has been researched along with ANS (Autonomic Nervous System) Diseases in 8 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We encountered severe autonomic neuropathy and cholestasis in a child receiving vincristine, after the introduction of piperacillin-tazobactam." | 3.78 | A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions? ( Andres, CR; Benz-de Bretagne, I; Gendrot, C; Jonville-Bera, AP; Jourdain, A; Le Guellec, C; Tarfaoui, N, 2012) |
| "Both lesions resolved only after treatment for Lyme disease was initiated." | 1.30 | Intestinal pseudoobstruction in acute Lyme disease: a case report. ( Chatila, R; Kapadia, CR, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Le Guellec, C | 1 |
| Benz-de Bretagne, I | 1 |
| Jonville-Bera, AP | 1 |
| Tarfaoui, N | 1 |
| Andres, CR | 1 |
| Gendrot, C | 1 |
| Jourdain, A | 1 |
| COHEN, EP | 1 |
| PETTY, TL | 1 |
| SZENTIVANYI, A | 1 |
| PRIEST, RE | 1 |
| Nakazato, Y | 1 |
| Tamura, N | 1 |
| Ohkuma, A | 1 |
| Yoshimaru, K | 1 |
| Shimazu, K | 1 |
| Ammendola, A | 1 |
| Sampaolo, S | 1 |
| Migliaresi, S | 1 |
| Ambrosone, L | 1 |
| Ammendola, E | 1 |
| Ciccone, G | 1 |
| Di Iorio, G | 1 |
| Gibbons, CH | 1 |
| Vernino, SA | 1 |
| Freeman, R | 1 |
| Poppe, G | 1 |
| Ludewig, W | 1 |
| Ludewig, H | 1 |
| Poppe, W | 1 |
| Chatila, R | 1 |
| Kapadia, CR | 1 |
| Cavaletti, G | 1 |
| Santoro, P | 1 |
| Agostoni, E | 1 |
| Zincone, A | 1 |
| Gori, C | 1 |
| Frattola, L | 1 |
| Tredici, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy.[NCT01522235] | Phase 2/Phase 3 | 6 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome, the change in systolic blood pressure during 60 degree tilt (ΔSBP), will be assessed in all study participants at baseline and at 6 weeks. (NCT01522235)
Timeframe: Baseline and 6 weeks
| Intervention | mmHg (Mean) |
|---|---|
| IVIg Group | 42.5 |
| Placebo Group | -12.3 |
To compare the change in systolic blood pressure during 60 degree head up tilt table test after 6 and 12 weeks of IVIG (the within-patient difference in ΔSBP at 12 and 6 weeks among treated patients). (NCT01522235)
Timeframe: 6 weeks and 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| IVIG Group | -26 |
| Placebo Group | -7.6 |
"To determine the change in autonomic symptoms (measured by the composite autonomic severity score [CASS]) measured at baseline and 6 weeks in individuals receiving IVIg.~Is a 10-point composite autonomic scoring scale of autonomic function. This scale allots 4 points for adrenergic and 3 points each for sudomotor and cardiovagal failure. Subjects with a score of 3 or less on have a mild autonomic failure, 4-6 have moderate autonomic failure and those with scores of 7 to 10 have severe failure. The minimum score possible is 3 and maximum is 10." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| IVIg Group | 0.5 |
| Placebo Group | 0 |
To determine the change in autonomic symptoms (measured by the composite autonomic symptom score [COMPASS] questionnaire) measured at baseline and 6 weeks. Minimum and maximum score possible: 0-100. We have reported the Total score. Higher values represent worse outcome. (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| IVIg Group | -5 |
| Placebo Group | -0.33 |
"To determine the change in quality of life (measured by the EuroQol [EQ-5D]) measured at baseline and 6 weeks in individuals receiving IVIg. We have reported the subscale (EQ-VAS). The minimum score is 0 and maximum score is 100. (0) corresponds to the worst health you can imagine, and the highest rate (100) corresponds to the best health you can imagine." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| IVIg Group | 15 |
| Placebo Group | 9.3 |
"To determine the change in orthostatic Hypotension symptom (measured by the orthostatic hypotension symptom assessment questionnaire) measured at baseline and 6 weeks in individuals receiving IVIG. This is a 60 point orthostatic hypotenstion symptom assessment questionnaire. The minimum score possible is 0 and maximum is 60.~Higher values represent worse outcome. We are reporting the total score." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| Group A | -9 |
| Group B | 12 |
1 trial available for prednisone and ANS (Autonomic Nervous System) Diseases
| Article | Year |
|---|---|
Autonomic neuropathy in mixed cryoglobulinemia.
Topics: Action Potentials; Adult; Aged; Autonomic Nervous System Diseases; Cross-Sectional Studies; Cryoglob | 2007 |
7 other studies available for prednisone and ANS (Autonomic Nervous System) Diseases
| Article | Year |
|---|---|
A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions?
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; ATP Binding Cassette T | 2012 |
CLINICAL AND PATHOLOGICAL OBSERVATIONS IN FATAL BRONCHIAL ASTHMA: REPORT OF A CASE TREATED WITH THE IMMUNOSUPPRESSIVE DRUG, AZATHIOPRINE.
Topics: Antineoplastic Agents; Asthma; Autonomic Nervous System Diseases; Azathioprine; Bronchodilator Agent | 1965 |
QSART in idiopathic pure sudomotor failure.
Topics: Adolescent; Autonomic Nervous System Diseases; Diagnostic Techniques, Neurological; Humans; Hypohidr | 2005 |
Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy.
Topics: Adult; Autoantibodies; Autoimmune Diseases of the Nervous System; Autonomic Nervous System Diseases; | 2008 |
[The shy-drager syndrom, a disease of second half of life (author's transl)].
Topics: Aged; Autonomic Nervous System Diseases; Bandages; Caffeine; Dexamethasone; Erectile Dysfunction; Fa | 1980 |
Intestinal pseudoobstruction in acute Lyme disease: a case report.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Autonomic Nervous System Diseases; Doxycycline; Fac | 1998 |
Chronic axonal sensory and autonomic polyneuropathy without motor involvement: a new 'chronic inflammatory neuropathy?'.
Topics: Autonomic Nervous System Diseases; Axons; Biopsy; Chronic Disease; Female; Humans; Inflammation; Mid | 1999 |